SignatureFD
AMLX icon

SignatureFD’s Amylyx Pharmaceuticals AMLX Stock Holding History

SignatureFD’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$4.1K Buy
141
+48
+52% +$1.27K ﹤0.01% 3004
2026
Q2 		$1.67K Sell
93
-161
-63% -$2.49K ﹤0.01% 3168
2026
Q1 		$3.53K Buy
+254
New +$3.57K ﹤0.01% 2894

Other funds holding AMLX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Franklin Resources
Franklin Resources San Mateo, California $474B AUM 32.39% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.23B AUM 121.47% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM

SignatureFD's AMLX Position: Q3 2026 in Review

SignatureFD increased its Amylyx Pharmaceuticals (AMLX) stake by 52% in Q3 2026, buying an estimated $1.27K and bringing the position to 141 shares worth $4.1K. The position accounts for ﹤0.01% of the portfolio, ranked #3004.

SignatureFD first reported a position in AMLX in Q1 2026 and has held it in 3 quarters since. 147 funds tracked by Wall St. Rank hold AMLX as of Q3 2026.

  • SignatureFD held 141 shares of Amylyx Pharmaceuticals worth $4.1K as of Q3 2026.
  • SignatureFD bought 48 Amylyx Pharmaceuticals shares in Q3 2026, an estimated $1.27K.
  • Amylyx Pharmaceuticals made up ﹤0.01% of SignatureFD's portfolio in Q3 2026, its #3004 holding.
  • SignatureFD first reported a position in Amylyx Pharmaceuticals in Q1 2026 and has held it in 3 quarters since.
  • 147 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q3 2026.

Based on SignatureFD's 13F filing for Q3 2026, filed 23 Oct 2026.